Stock Sale, Buyback News

LUXEMBOURG--(BUSINESS WIRE)--Eurofins Scientific SE (Paris:ERF) (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below. This notification is made in accordance with the European Market Abuse Regulation. NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM     1. Details of the p...

BOCA RATON, Fla.--(BUSINESS WIRE)--DigitalBridge Group, Inc. (“DigitalBridge”), a leading global investor in digital infrastructure, today announced that, as a result of its acquisition by affiliates of SoftBank Group Corp. on September 30, 2026 (the “Transaction”), holders of its 7.125% Series H Cumulative Redeemable Perpetual Preferred Stock (the “Series H Preferred Stock”) will have the right, until the close of business on October 28, 2026, to convert each share of Series H Preferred Stock...

NEW YORK--(BUSINESS WIRE)--Silvia, Inc. (Nasdaq: SVIA) (the “Company”), formerly ProCap Financial, Inc., the first publicly traded agentic finance firm, today announced that since September 22, 2026 it repurchased an additional 5% of shares of its common stock. Since the start of its share buyback program, the Company has repurchased shares equal to approximately 20% of the shares outstanding at the inception of the program. As of market close October 6, 2026, the number of outstanding shares w...

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a clinical-stage target oncology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on October 1, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 120,900 shares of common stock and 7,200 restricted stock units (“...

LA DÉFENSE, France--(BUSINESS WIRE)--Regulatory News: In accordance with applicable regulations, Arkema (Paris:AKE) announces having carried out the following share buyback transactions in accordance with Article 5 §2 of Regulation (EU) No 596/2014 from 28 September to 02 October 2026. Name of the issuer Issuer identifier code Day of the transaction Financial instrument identifier code Total daily volume (number of shares) Weighted average price of daily acquisition Market identifier code ARKEM...

PARIS--(BUSINESS WIRE)--Regulatory News: In accordance with the authorizations given by the shareholders’ general meeting on May 29, 2026, to trade on its shares and pursuant to applicable law on share repurchase, TotalEnergies SE (Paris:TTE) (LSE:TTE) (NYSE:TTE) (LEI: 529900S21EQ1BO4ESM68) declares the following purchases of its own shares (FR0000120271) from September 28 to October 2, 2026: Transaction Date Total daily volume (number of shares) Daily weighted average purchase price of shares...

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced the grant of an inducement award to one new hire in Sept. 2026, as required under Nasdaq Listing Rule 5635(c)(4)....

ASHEVILLE, N.C.--(BUSINESS WIRE)--HomeTrust Bancshares, Inc. (the “Company”) (NYSE: HTB), the holding company for HomeTrust Bank, announces the completion of its 5% stock repurchase program, which began in August 2026. A total of 832,000 shares were repurchased at an average price of $47.70 per share. In addition, the Company's Board of Directors has authorized the repurchase of up to an additional 790,000 shares of the Company’s common stock, representing approximately 5% of the Company’s curr...

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of 380,500 restricted stock units (RSUs) to 24 new employees and stock options to purchase 50,000 shares of its common stock to one new employee. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee’s acceptance of employment with Vera...

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 8,340 shares of the Company’s common stock to five new employees (the “Inducement Grants”) on October 5, 2026 (the “Grant Date”). The Induce...